{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:33Z","timestamp":1791475353758,"version":"4.3.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008616","name":"RUSH UNIVERSITY","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008616","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ecl.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T08:58:54Z","timestamp":1727168334000},"page":"559-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prevention and Management of Denosumab Discontinuation Rebound Fractures"],"prefix":"10.1016","volume":"53","author":[{"given":"Sumeet","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.002_bib3","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1007\/s10067-021-05757-w","article-title":"Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?","volume":"40","author":"Miedany","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.002_bib7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial1","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib9","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporosis Int"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib10","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporosis Int"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.002_bib12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized Placebo-Controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cen.13867","article-title":"Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman","volume":"90","author":"De Sousa","year":"2019","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine"},{"issue":"8S","key":"10.1016\/j.ecl.2024.08.002_bib18","doi-asserted-by":"crossref","first-page":"S581","DOI":"10.1097\/RHU.0000000000000979","article-title":"Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases","volume":"27","author":"Anagnostis","year":"2021","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.ecl.2024.08.002_bib19","doi-asserted-by":"crossref","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00198-017-4334-3","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis","volume":"29","author":"Niimi","year":"2018","journal-title":"Osteoporosis Int"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00198-018-4793-1","article-title":"Vertebral fractures cascade: potential causes and risk factors","volume":"30","author":"Che","year":"2019","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.ecl.2024.08.002_bib22","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2024.08.002_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bone.2017.12.015","article-title":"Rebound vertebral fracture in the dental chair during a tooth extraction whilst on a treatment holiday from denosumab to avoid ONJ","volume":"108","author":"Leaney","year":"2018","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semarthrit.2019.02.007","article-title":"Spontaneous vertebral fractures after denosumab discontinuation: a case collection and review of the literature","volume":"49","author":"Florez","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ecl.2024.08.002_bib27","unstructured":"Fern\u00e1ndez Fern\u00e1ndez E, Benavent N\u00fa\u00f1ez D, Bonilla Hern\u00e1n G, et al. Multiple vertebral fractures following discontinuation of denosumab treatment: ten clinical cases report. Reumatolog\u00eda Cl\u00ednica (English Edition), Available at: https:\/\/www.reumatologiaclinica.org\/en-multiple-vertebral-fractures-following-discontinuation-articulo-S2173574320301209. (Accessed 7 July 2024)."},{"issue":"4","key":"10.1016\/j.ecl.2024.08.002_bib28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-021-06274-x","article-title":"COVID pandemic and denosumab adherence","volume":"33","author":"Minisola","year":"2022","journal-title":"Osteoporosis Int"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbspin.2019.07.010","article-title":"Rebound-associated vertebral fractures after stopping denosumab: report of four cases","volume":"87","author":"Dupont","year":"2020","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/M20-0882","article-title":"Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study","volume":"173","author":"Lyu","year":"2020","journal-title":"Ann Intern Med"},{"issue":"S1","key":"10.1016\/j.ecl.2024.08.002_bib31","volume":"33","author":"Pfeiler","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00198-023-06894-5","article-title":"Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series","volume":"35","author":"Clifton Goldney","year":"2024","journal-title":"Osteoporosis Int"},{"issue":"12","key":"10.1016\/j.ecl.2024.08.002_bib33","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-Year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.ecl.2024.08.002_bib35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ecl.2024.08.002_bib37","unstructured":"Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, et al. Clinical features of 35 patients with 172 spontaneous vertebral fractures after denosumab discontinuation: a single center observational study. ASBMR 2018 Annual Meeting. Montr\u00e8al, Queb\u00e8c, Canada, September 28, 2018 to October 1, 2018, Abstract number 1008."},{"issue":"11","key":"10.1016\/j.ecl.2024.08.002_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0141076819861027","article-title":"Hip fractures following denosumab discontinuation: three clinical cases reports","volume":"112","author":"Henr\u00edquez","year":"2019","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.ecl.2024.08.002_bib39","doi-asserted-by":"crossref","first-page":"116925","DOI":"10.1016\/j.bone.2023.116925","article-title":"Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: a retrospective study of patients with osteoporosis in a real-world clinical setting","volume":"177","author":"Cruchelow","year":"2023","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.23736\/S0391-1977.20.03137-5","article-title":"Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab","volume":"45","author":"Betella","year":"2020","journal-title":"Minerva Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.002_bib41","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00198-023-06845-0","article-title":"Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients","volume":"34","author":"Tsai","year":"2023","journal-title":"Osteoporosis Int"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1507\/endocrj.EJ19-0198","article-title":"Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab","volume":"67","author":"Uchida","year":"2020","journal-title":"Endocr J"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.ecl.2024.08.002_bib44","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bone.2018.12.012","article-title":"Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: case report and brief literature review","volume":"120","author":"Roux","year":"2019","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib45","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","article-title":"Hypercalcemia after discontinuation of long-term denosumab treatment","volume":"27","author":"Koldkj\u00e6r S\u00f8lling","year":"2016","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib46","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib47","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-Year randomized study","volume":"36","author":"S\u00f8lling","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.002_bib49","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2024.08.002_bib50","doi-asserted-by":"crossref","first-page":"116764","DOI":"10.1016\/j.bone.2023.116764","article-title":"Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. the ReoLaus study","volume":"172","author":"Liebich","year":"2023","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib52","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A\u00a0single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"issue":"S1","key":"10.1016\/j.ecl.2024.08.002_bib53","first-page":"3","article-title":"Vertebral fracture incidence after discontinuation of denosumab treatment: analysis from freedom and its extension","volume":"38","author":"Ferrari","year":"2017","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.ecl.2024.08.002_bib54","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporosis Int"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ecl.2024.08.002_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib58","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","article-title":"Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports","volume":"30","author":"Lamy","year":"2019","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ecl.2024.08.002_bib59","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.56.P188","article-title":"Bone mineral density decline following denosumab discontinuation might not be attenuated with previous bisphosphonate therapy","author":"Japelj","year":"2018","journal-title":"Endocr Abstr"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","article-title":"The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial","volume":"35","author":"Ramchand","year":"2024","journal-title":"Osteoporosis Int"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jocd.2006.10.004","article-title":"Effect of bone strontium on BMD measurements","volume":"10","author":"Blake","year":"2007","journal-title":"J\u00a0Clin Densitom"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.002_bib63","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00198-023-07000-5","article-title":"Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment","volume":"35","author":"Makras","year":"2024","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.002_bib66","doi-asserted-by":"crossref","first-page":"e10396","DOI":"10.1002\/jbm4.10396","article-title":"Failure of oral risedronate therapy to prevent spontaneous vertebral fracture in a patient ceasing denosumab: a cautionary case","volume":"4","author":"Davidoff","year":"2020","journal-title":"JBMR Plus"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.002_bib67","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ecl.2024.08.002_bib68","doi-asserted-by":"crossref","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","article-title":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"138","author":"Makras","year":"2020","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.002_bib69","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-023-01119-7","article-title":"The five-year effect of a single zoledronate infusion on bone mineral density following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"113","author":"Anastasilakis","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.002_bib70","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","volume":"28","author":"Lehmann","year":"2017","journal-title":"Osteoporosis Int"},{"issue":"6","key":"10.1016\/j.ecl.2024.08.002_bib71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","article-title":"Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment","volume":"38","author":"Kondo","year":"2020","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"S1","key":"10.1016\/j.ecl.2024.08.002_bib72","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/jbmr.3936","article-title":"2019 annual meeting of the American society for bone and mineral research orange county convention center, Orlando, Florida, USA September 20\u201323, 2019","volume":"34","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2024.08.002_bib73","unstructured":"Fu S. The optimal sequential therapy after long term denosumab treatment. ClinicalTrials.gov Web site, Available at: https:\/\/clinicaltrials.gov\/study\/NCT05091099. (Accessed 10 July 2024)."},{"issue":"12","key":"10.1016\/j.ecl.2024.08.002_bib74","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporosis Int"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib75","doi-asserted-by":"crossref","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12\u00a0months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2024.08.002_bib76","first-page":"bvad114","article-title":"OR13-06 romosozumab after denosumab improves lumbar spine bone mineral density and microarchitecture greater than denosumab continuation in postmenopausal women","volume":"7","author":"Hong","year":"2023","journal-title":"J\u00a0Endocr Soc"},{"issue":"6","key":"10.1016\/j.ecl.2024.08.002_bib77","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","article-title":"Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment","volume":"33","author":"Tominaga","year":"2022","journal-title":"Osteoporosis Int"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib78","doi-asserted-by":"crossref","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ecl.2024.08.002_bib79","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.bonr.2020.100288","article-title":"Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report","volume":"13","author":"Kashii","year":"2020","journal-title":"Bone Reports"},{"key":"10.1016\/j.ecl.2024.08.002_bib80","doi-asserted-by":"crossref","first-page":"105754","DOI":"10.1016\/j.jbspin.2024.105754","article-title":"Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report","author":"Krikelis","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ecl.2024.08.002_bib81","article-title":"A\u00a0novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis","author":"Kumar","year":"2024","journal-title":"Osteoporosis Int"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib82","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","article-title":"Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women","volume":"33","author":"Ha","year":"2022","journal-title":"Osteoporosis Int"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib83","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","article-title":"Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis","volume":"31","author":"Ebina","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib84","first-page":"5432751","article-title":"Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation","volume":"2018","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Case Reports in Rheumatology"},{"issue":"12","key":"10.1016\/j.ecl.2024.08.002_bib85","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-Year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib86","doi-asserted-by":"crossref","first-page":"e10731","DOI":"10.1002\/jbm4.10731","article-title":"Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine","volume":"7","author":"Laroche","year":"2023","journal-title":"JBMR Plus"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib87","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","article-title":"Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60\u00a0mg dose: a prospective observational study","volume":"80","author":"Khan","year":"2023","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.002_bib88","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12020-020-02333-1","article-title":"Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation","volume":"69","author":"Anastasilakis","year":"2020","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.002_bib89","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10067-005-0159-0","article-title":"Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study","volume":"25","author":"Laroche","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.ecl.2024.08.002_bib90","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00198-006-0169-z","article-title":"Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study","volume":"17","author":"Armingeat","year":"2006","journal-title":"Osteoporosis Int"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jos.2016.11.017","article-title":"Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures","volume":"22","author":"Tetsunaga","year":"2017","journal-title":"J\u00a0Orthop Sci"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.002_bib92","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jocd.2021.01.006","article-title":"Efficacy of antiosteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation","volume":"24","author":"Anastasilakis","year":"2021","journal-title":"J\u00a0Clin Densitom"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib93","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jocd.2020.10.014","article-title":"Progression of rebound-associated vertebral fractures following denosumab discontinuation despite reinstitution of treatment: suppressing increased bone turnover may not be enough","volume":"24","author":"Anastasilakis","year":"2021","journal-title":"J\u00a0Clin Densitom"},{"issue":"9886","key":"10.1016\/j.ecl.2024.08.002_bib94","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"9999","key":"10.1016\/j.ecl.2024.08.002_bib95","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.002_bib96","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00198-019-04963-2","article-title":"Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study","volume":"30","author":"Borek","year":"2019","journal-title":"Osteoporosis Int"},{"issue":"12","key":"10.1016\/j.ecl.2024.08.002_bib97","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jbmr.4930","article-title":"Denosumab and mortality in a real-world setting: a comparative study","volume":"38","author":"Alarkawi","year":"2023","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.002_bib98","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.joms.2022.10.014","article-title":"What is the risk of developing osteonecrosis following dental extractions for patients on denosumab for osteoporosis?","volume":"81","author":"Colella","year":"2023","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib99","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00198-014-2871-6","article-title":"Persistence at 12\u00a0months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study","volume":"26","author":"Silverman","year":"2015","journal-title":"Osteoporosis Int"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.002_bib100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11657-022-01065-1","article-title":"Stop the denosumab delay! the effect of implementing an automatic reminder in the electronic medical record","volume":"17","author":"Zaman","year":"2022","journal-title":"Arch Osteoporosis"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.002_bib102","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00198-021-05961-z","article-title":"Association between outdoor particulate air pollution and the risk of osteoporosis: a systematic review and meta-analysis","volume":"32","author":"Liu","year":"2021","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.002_bib101","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1210\/jc.2019-00777","article-title":"Response to letter to the editor: \u201cPharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline\u201d","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T15:13:41Z","timestamp":1729610021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852924000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0889852924000598"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2024.08.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and Management of Denosumab Discontinuation Rebound Fractures","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}